Epitope-based vaccines have revolutionized vaccine research in the last decades. Due to their complex nature, bioinformatics plays a pivotal role in their development. However, existing algorithms address only specific parts of the design process or are unable to provide 15 formal guarantees on the quality of the solution. Here we present a unifying formalism of the general epitope vaccine design problem that tackles all phases of the design process simultaneously and combines all prevalent design principles. We then demonstrate how to formulate the developed formalism as an integer linear program which guarantees optimality of the designs. This makes it possible to explore new regions of the vaccine design space, analyze the 20 trade-offs between the design phases, and balance the many requirements of vaccines.
Introduction contrast, the mosaic design problem is concerned with constructing an artificial antigen P of fixed length h comprised of potentially overlapping epitopes with maximal efficacy I(P ). These design principles can be further generalized to allow the composition of a cocktail of several poylpeptides 80 that jointly optimize the vaccine efficacy, thereby reducing the overall length of the fragments without sacrificing other properties of the vaccine.
These three design principles can be unified under a single mathematical framework ( Figure 1B and C). We formulate the generalized EV design problem as a combinatorial optimization problem on a weighted, directed graph G(V, E, w), where the vertices V represent the epitopes and the 85 the weight w(·) of the edges E determine the design of the EV. We also add an artificial node s representing the N-and C-terminus of the vaccine, connecting it to every vertex v ∈ V such that w(e sv ) = a and w(e vs ) = b, with design-dependent weights a, b ∈ R. To find the optimal EV in G(Ṽ ,Ẽ, w), withṼ = V ∪ {s} andẼ = E ∪ {(s, v), (v, s)|v ∈ V }, we are seeking n disjoint subsets P 1 , . . . , P n ⊆Ṽ , each of size at most k, that together maximize the vaccine's immunogenicity 90 I : 2 V → R, and whose simple tours H(P 1 ), . . . , H(P n ) start and end at s ∈Ṽ and weigh at most h ∈ R (Eq. 1). Here we use the term simple tour to refer to a closed walk with no repeated vertices except for s.
Subject to e∈H(Pi) w(e) ≤ h i = 1, . . . , n |P i | ≤ k i = 1, . . . , n P i ∩ P j = ∅ i, j = 1, . . . , n i = j s ∈ P i i = 1, . . . , n Where P i ⊆ V i = 1, . . . , n I(P ) is the immunogenicity of P ⊆ V H(P i ) is a simple tour visiting the vertices in P i i = 1, . . . , n
Similar constrained design problems appear in genome assembly [21] , and have been extensively studied in the field of operations research under the name of price collecting traveling salesperson, 95 bank robber, or team orienteering problem [22] . Importantly, they are known to be NP-hard [23] .
While it is unclear what a good vaccine immunogenicity function I(P ) constitutes, we only will define vaccine efficacy vaguely as the ability to induce a broad immunization in a target population represented by a set of prevalent HLA molecules against a given polymorphic antigen pool, and refer to immunogenicity functions introduced in the context of rational vaccine design [12, 13, 16, 17] . 100 However, for the purpose of algorithmic analysis and comparison, we use the function proposed by Toussaint et al. [13] , which assumes that each epitope contributes independently to the vaccine's overall immunogenicity with respect to the target population represented by a set of HLA alleles:
where p a is the observed frequency of HLA allele a ∈ A within the target population and i va is the individual immunogenicity generated by epitope v bound to HLA molecule a. We approximate the 105 latter with the log-transformed IC 50 binding strength between the epitope and the MHC complex, which can be predicted by machine learning algorithms such as NetMHCpan [24] .
Adaptations for epitope mixture design
To design epitope mixture vaccines with the proposed framework, we ignore the edge weight constraint by setting h = ∞, and the edge weights w(e ij ) = 0 for e ij ∈Ẽ ( Figure 1C (a)). The size 110 k of P , however, has to be defined. Note that this is equivalent to the framework proposed by Toussaint et al. [13] .
Adaptations for string-of-beads design
To enable string-of-beads designs with the framework, we interpret the edge weights w(e ij ) as the negative proteasomal cleavage log-likelihood between epitope v i and v j , and set the out-and in-115 going edges of node s to w(e sv ) = w(e vs ) = 0 for every v ∈ V ( Figure 1C (b)), following [14] . The proteasomal cleavage likelihood of an epitope can be predicted with existing proteasomal cleavage site methods such as ProteaSMM [25] , PCM [26] , or NetChop [27] .
Solving the so-defined generalized EV design problem yields the string-of-beads design with maximal immunogenicity, whose overall cleavage likelihood is at least h. Predetermining h, how-120 ever, is difficult. We might not even be interested in a solution with a fixed h, but rather want to explore the inter-dependencies between the immunogenicity objective and the overall cleavage likelihood of the string-of-beads EV. This leads to a reinterpretation of the design formulation as bi-objective optimization problem, in which we simultaneously optimize the overall immunogenicity I(P ) and the length of the tours H(P i ), i = 1, . . . , n (i.e., the overall cleavage likelihood). We can 125 then explore the Pareto frontier of this problem with methods such as the augmented -constraint [28] (section A in Supplement 1).
Adaptations for mosaic design
For mosaic vaccines, we define the edge weight w(e ij ) as the length that would be added to the mosaic antigen once v i and v j are joined at their longest suffix-prefix overlap ( Figure 1C (c)):
where |v j | represents the length of the epitope sequence v j and v i [l :], v j [: l] represent the substrings of length l of epitopes i and j starting and ending at position l respectively. Note that Eq. 3 can be computed efficiently in time O(m + k 2 ) for a given set of k strings of total length m by using generalized suffix trees [29] . Furthermore, we define the weights of the out-and in-going edges of node s as w(e sv ) = |v| and w(e vs ) = 0 for all v ∈ V . The edge-weight sum of any tour that 135 starts and ends at s is then equal to the length in amino acids of the resulting mosaic sequence.
Formulation as an integer linear program guarantees optimally
With the aforementioned definitions, we can formulate the generalized EV design problem as an integer linear program (ILP) encoding the team orienteering problem [22] . This guarantees to construct an optimal EV with the cost of potentially long run times and/or memory requirements, x vst = |T | Leave from and return to s Every tour represents a single polypeptide. We introduce binary decision variables x vwt and y vt indicating whether the tour t is visiting the edge between v and w and the vertex v, respectively.
We enforce the consistency between these decision variables with the constraint C1. We also have 145 to ensure that every node is visited at most once (C2) and the tour is connected and starts from and ends in s (C3). We then constrain the edge weight limit (C4) and the length (C5) of each tour.
Additionally, we include constraints to eliminate potential subtours (i.e., solutions that include two or more disconnected tours) in C6. We are using the Miller-Tucker-Zemlin formulation [30] , but any other formulation could be used as well. This was done for computational ease, as well as to study the variability and the generalizability of the results. The remaining steps of the pipeline, including the evaluation, were executed separately for each subset and the results aggregated at the end.
reproduced in Supplement 2, which together provide a maximum theoretical coverage of 91.3% of the world population.
Epitopes: The binding affinities between peptides and HLA alleles were predicted with NetMHCpan [24] . No filtering was done unless explicitly stated.
Cleavage likelihood:
The cleavage likelihoods between all pairs of epitopes, necessary for the 175 string-of-beads design, were predicted using PCM scores [26] . The negative cleavage likelihood of a sequence composed of two joined epitopes e i and e j , with e i of length , was computed by adding to the negative cleavage score at the correct position (i.e., between e i and e j ) the cleavage scores at K wrong positions around , weighted by a factor 0 ≤ β ≤ 1: 
Evaluation Metrics
Given a set of epitopes P comprising the vaccine, we compute the following metrics, in addition to the immunogenicity I(P ):
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Population Coverage: Given a set of HLA alleles A, we define the population coverage of P as the probability that a person has at least one HLA allele binding to one or more epitopes of P
[14]:
where A i is the set of alleles of locus i, p a is the probability that a person has this allele, and y a is a binary variable indicating whether P contains an epitope binding to a. Binding was determined 190 by an IC 50 affinity of at most 5000 nM. Note that the graph can contain some epitopes that do not bind to any HLA allele.
We will only show the population coverage relative to the maximum that can be achieved with the given set of alleles, so that 100% relative coverage corresponds to 93.1% actual coverage.
Pathogen Coverage: The number of distinct pathogens that contain at least one epitope of P .
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Conservation: The average of the conservation of each epitope in P . The conservation of an epitope is the number of proteins that contain it. High conservation indicates low mutation rate, hence importance for the correct functioning of the pathogen.
Results
Jointly approaching epitope selection and assembly captures trade-off This risk can be managed with our framework by appropriately setting h, the maximum total negative cleavage log-likelihood between all epitopes of the vaccine. Interpreting and predetermining this quantity is, however, difficult. For each of the five bootstraps, we generated several Pareto-efficient solutions to illustrate the trade-off between correct cleavage and high immuno-210 genicity.
Cleavage likelihood can be increased considerably with small losses in immunogenicity up until a certain point, after which the latter quickly drops to provide only modest improvements in cleavage ( Figure 2 ). Notably, it is possible to achieve 84-88% of the maximum cleavage score with only a 15-20% reduction in immunogenicity. In practice, the effective immunogenicity for vaccines 215 with low cleavage likelihood is smaller than the theoretical immunogenicity, as the vaccine is more likely to be cleaved incorrectly. Consequently, the cleavage likelihood should be favored more than immunogenicity when choosing the design parameters.
Sequential approaches such as OptiTope [13] are only able to generate the highest-immunogenicity solutions, as they do not consider the subsequent assembly phase as all. These methods simply 220 cannot be used to balance the quality of selection and assembly.
Joint design of polypeptide cocktails increases immunogenicity without sacrifices A large number of epitopes might be necessary to create a vaccine meeting extreme requirements.
Long polypeptides, however, are harder to manufacture [33, 34] and, in practice, most synthetic 225 vaccines tested so far are composed of sequences of 10 to 50 amino acids [4, [35] [36] [37] [38] . Our framework can be used to design a vaccine that meets extreme requirements with short polypeptides that are optimized simultaneously, and can be synthesized in parallel for a fraction of the cost and time.
An epitope mixture designed by OptiTope [13] needs at least 24 epitopes to cover 99% of the complete set of pathogens, but 216 amino acids might be too many for a single string-of-beads 230 polypeptide. We, therefore, designed a vaccine composed of four separate mosaic polypeptides of 54 amino acids each. We also designed a single mosaic of 216 amino acids with no coverage enforced as a baseline. The mosaic cocktail was designed by considering the union of the 2000 epitopes with highest immunogenicity and the 2000 epitopes with highest pathogen coverage.
The resulting four polypeptides together have roughly twice the conservation and the immuno-235 genicity as the epitope mixture ( Figure 3 ). Most notably, none of them reach the required pathogen coverage in isolation; only when considered jointly they cover the required number of pathogens.
The unconstrained single mosaic vaccine already covers 96% of the pathogens even though its epitopes have the lowest conservation among the three vaccines. Unsurprisingly, it also has the largest immunogenicity, almost 20% more than the polypeptide cocktail and 260% more than the Mosaic design greatly increases immunogenicity and pathogen coverage compared to string-of-beads
By leveraging overlaps, the mosaic design is able to include more epitopes in the same number of amino acids, resulting in improved immunogenicity and coverage compared to the string-of-beads 245 design (Figure 4 ). This occurs as the enforced overlap cannot be sustained by the limited variety of the input epitopes. By relaxing this constraint to only four amino acids, we can produce pseudomosaic vaccines that contain less epitopes than the theoretical maximum, but have, nonetheless, much higher immunogenicity than the string-of-beads alternative. It is also evident that mosaic vaccines can inherently reach higher pathogen coverage with shorter polypeptides, even when no 250 such constraint is imposed on the design. Conservation, however, remains mediocre.
Short mosaic vaccines achieve very high coverage
We designed mosaic vaccines with a single polypeptide on each of the five bootstraps following the genetic algorithm introduced by Fisher et al. [19, 39] , using the recommended parameter settings (notably, unlike our framework, the length of the polypeptides cannot be specified). We then used our framework to design a mosaic vaccine of the same length (206 amino acids), with at least the same pathogen and population coverage and epitope conservation. This results in very similar mosaics with essentially the same properties: the same 26 HLA alleles covered out of 27, 99.1% of pathogens covered, an average epitope conservation of 28%, and immunogenicity of 10.8. However, Fisher et al. optimize for coverage, not for immunogenicity. If we do the same, we are able to 260 achieve the same properties with a reduction in epitopes of about 50%.
Long mosaic vaccines inherently target conserved regions
The previous experiments show that mosaic vaccines can reach very good pathogen coverage with ease. Intrigued by this characteristic, we studied and compared the exact positions covered by the epitopes of mosaic and string-of-beads vaccines.
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The vaccines were designed on the complete pathogen set. The string-of-beads contained 20 epitopes, the short mosaic vaccine 28 amino acids, and the long mosaic vaccine 90 amino acids. We then aligned the sequences using MAFFT [40] and counted how many epitopes cover every position.
We also computed the potential immunogenicity as the sum of the immunogenicities of all the epitopes covering that position, and used position-specific entropy to quantify the variation among 270 sequences (section B in Supplement 1). Finally, we ignored the positions where the consensus (majority) was a gap.
Analyzing the epitopes included in the vaccines showed that they do not appear in random positions of the pathogens, but are concentrated in a few distinct regions that differ between vaccines (Figure 5 B) . It is evident that string-of-beads vaccines, cleavage requirements aside, target 275 the most immunogenic regions with no regards for their conservation, whereas mosaic vaccines, especially longer ones, prefer to focus on conserved regions. These correlations, as quantified by the Spearman coefficient, are generally weak or moderate, but statistically significant (Figure 5 C) .
The epitope mixture's coverage was well correlated with immunogenicity (r = 0.617, p=4 · 10 −22 ), but not with entropy (r = 0.066, p = 4 · 10 −1 ). The long mosaic vaccine seeked immunogenic 280 (r = 0.350, p = 4·10 −7 ), but low entropy regions (r = −0.353, p = 3·10 −7 ). Interestingly, the short mosaic vaccine covered an entirely different region and was correlated with both immunogenicity (r = 0.228, p = 1 · 10 −3 ) and entropy (r = 0.410, 2 · 10 −9 ). Entropy and immunogenicity are, curiously, not correlated (r = −0.015, p = 8 · 10 −1 ).
Mosaic vaccines should be designed with epitope conservation in mind 285
There is growing evidence that effective vaccines for highly variable viruses such as the Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), as well as diseases such as Malaria, Cancer, and Influenza should target conserved epitopes [41] [42] [43] [44] [45] . Some of our previous experiments clearly showed that mosaic vaccines have a natural tendency to spontaneously achieve high pathogen coverage, even though the conservation of the individual epitopes in the vaccine remains 290 low.
We modified the ILP formulation to maximize average epitope conservation and pathogen coverage together with immunogenicity (Supplement 3). We then compared mosaic vaccines of growing sizes optimized against these three criteria ( Figure 6 ). Since immunogenicity is a couple of orders of magnitude smaller than the other two, it will only be optimized when further improvements 295 in conservation or coverage are practically insignificant. The average epitope conservation can be greatly improved until around 40%, and it comes with increased pathogen coverage compared to mosaic vaccines optimized for immunogenicity. Most epitopes have very poor conservation, which means that optimizing its average becomes harder as the vaccine size increases. In fact, conservation decreases for longer vaccines. Moreover, immunogenicity grows more slowly when conservation 300 is optimized: it is on par with pathogen coverage-optimized vaccines for short mosaic designs, but is almost 30% smaller for long mosaic designs.
This suggests that the best results are obtained with short mosaic vaccines designed to have high average epitope conservation. Besides having considerably larger conservation, both their immunogenicity and their pathogen coverage are still close to the theoretical maximum. As the mosaic 305 designs become longer, this gap widens, and so-designed vaccines lose their advantages. However, we have shown previously that long vaccines can be replaced by cocktails of short polypeptides with essentially the same joint properties.
Vaccines designed on small subsets generalize to the full dataset
Some of the previous results were obtained by only considering 300 random proteins out of a few 310 thousand, and the cocktail only used a subset of about 4000 out of 52712 epitopes. One naturally wonders whether the produced vaccines are as good on the general pathogen population.
The only quantities that can change, for a given vaccine, are epitope conservation and pathogen coverage, while designing a vaccine de novo can result in higher immunogenicity. We use the same setting of the experiment where we compared with Fischer et al and consider it representative of 315 the others, since we mostly focused our attention to mosaics. We evaluated the mosaics designed on the five bootstrap on the set of all pathogens, and quantified the differences in the evaluation metrics. This revealed that there was no difference on conservation (paired t-test, t = 0.04, p = 0.487) between the small subsets and the full set, but pathogen coverage slightly decreased both for our design and for Fischer et al.'s (t = 2.77, p = 0.025, from 99.1%, std. 0.4% to 98.7%, 320 std. 0.2%; similar quantities for [19] ). As for immunogenicity, a string-of-beads with 10 epitopes and no constraints achieved an immunogenicity of 3.08 on the full set, just 10% higher than what could be achieved with the same settings on the smaller sets in the Pareto frontier experiment.
A 216-amino acids mosaic in the same setting of the cocktail experiment, but designed on all the epitopes, improved immunogenicity by 18% (from 14.55 to 17.23), but worsened coverage by 1% 325 (from 96.3% to 95.0%) and conservation by 41% (from 6.1% to 3.6%), suggesting that subsetting epitopes should be done with greater care.
It might seem surprising that vaccines developed on roughly 15% of the pathogens generalize to a larger population. However, peptides with high coverage and conservation on a large population are likely to be so also on random subsets of it. In fact, even though each of the five random subsets 330 contains only about 25% of the peptides found in the full pathogen set, the pairwise overlap is between 46 and 48%, and 27% of their peptides are shared among all five sets.
Discussion and conclusion
Epitope-based vaccine (EV) design has thriven in recent years, and multiple design principle have emerged aided by the heavy use of bioinformatics approaches. However, most proposed design 335 algorithms are lacking in one of several dimensions: they model only individual stages of the entire design problem (e.g., [13, 15] ), use ad hoc heuristics (e.g., [16] ), or optimization algorithms that cannot guarantee convergence to the optimal solution (e.g., [12, 19] ).
Here we proposed a graph-theoretical formalism for EV design that models the complete design process and includes every prevalent design principle as special case. We showed how to formulate 340 this optimization problem as an integer linear program to obtain an guaranteed optimal solution.
This, in turn, enables informed choices throughout the design process by accurately and reliably determining the trade-offs involved: for example, we precisely quantified the decrease in immunogenicity that has to be paid to achieve gains in other metrics such as coverage and conservation, and showed the advantage of mosaic over string-of-beads designs under our modeling assumptions.
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In practice, we might be overestimating mosaics' immunogenicity, as our framework does not model their cleavage by the proteasome, which means that we have no control over which epitopes will actually be recovered. Their successes in recent clinical trials [5-10, 17], however, suggest that their advantage over string-of-beads is, nonetheless, real. Jointly approaching the selection and assembly problems enables the exploration of new possibilities in the EV design space. We demonstrated this 350 by investigating the trade-off between immunogenicity and cleavage likelihood in string-of-beads designs, and by creating the optimal cocktail of mosaic polypeptides for a given coverage whose design would be impossible with iterative, stage-wise optimization methods. Our results also show that it is easy to reach very good population coverage by virtue of our definition of immunogenicity based on HLA binding. Finally, convergence and optimality guarantees of linear programming 355 solvers allow us to find solutions that are, sometimes, substantially better than those found by optimization algorithms that lack these guarantees.
The price to pay for the increased modeling power is increased computational resources needed to solve the graph optimization problem. Being based on the team orienteering problem, EV design with our framework is a NP-hard problem, and the size of the graph grows quadratically with the 360 number of epitopes in consideration. However, we conducted several experiments on subsets of the pathogens or the epitopes, and showed that results obtained in this way are only slightly worse than what can be obtained by considering the complete set of pathogens/epitopes. We argued that this is possible because highly conserved epitopes are likely to abound in smaller subsets of the pathogen sequences too. This means that such graphs can easily be pruned, resulting in much 365 smaller problems that can be solved in reasonable time without compromising the quality of the final solution. Alternatively, the solver can be interrupted early when the current solution is within a few percents of the optimal one. ILP solvers iteratively improve a candidate solution and an upper bound on the objective of the optimal solution at the same time [46] . This gap tells us the maximum distance between the candidate solution and the optimal one: when they match, the 370 current solution is optimal. Empirically, in our setting, most of the time is spent on improving solutions that are only at most 2%-5% away from the optimal one. Therefore, the solver can be safely interrupted early on a good quality solution. ILP solvers are complex machinery governed by several parameters that affect how they search for a solution, and, therefore, how much time they need. Different types of problems benefit from different parameter settings. Therefore, further to reduce the time needed to find a solution [47] [48] [49] . Another limitation is that our formulation as an ILP limits the expressiveness of objectives and constraints to linear forms. The graph formalism in Eq. 1, however, remains valid even for complex, non-linear constraints and objectives. In this case, more flexible optimization methods have to be used, but the optimality guarantees can be 380 lost.
To conclude, the proposed framework enables the design of correctly cleaved string-of-beads vaccines with the largest possible immunogenicity under this constraint. It also enables the exploration of the Pareto frontier between these two competing properties to find the optimal design that best reflects the envisioned trade-off. At the same time, our framework can be used to de-385 compose long vaccines in shorter polypeptides that, together, maintain the properties of the longer sequence. This makes the resulting vaccine easier, cheaper, and quicker to synthesize. Finally, we showed that conservation should be emphasized over coverage for mosaic vaccines.
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